Alymsys Injection, Solution
Product Images NDC 70121-1755

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Alymsys (NDC 70121-1755). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Amneal Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Alymsys Bevacizumab Maly Injection 1)

A Kaplan-Meier survival curve chart comparing proportion surviving over a duration of up to 30 months. The chart has two lines: a red line for IFL + Placebo and a blue line for IFL + Bevacizumab, showing survival over time in months. The number of patients at risk at various time points is noted below the x-axis.*

FDA Label Image

400mg Carton (Alymsys Bevacizumab Maly Injection 10)

Packaging label for Alymsys (bevacizumab-maly) injection, solution 400 mg/16 mL (25 mg/mL) for intravenous infusion after dilution. The label includes the NDC 70121-1755-1 and states the product is manufactured by Amneal Pharmaceuticals LLC. It specifies a 16 mL single-dose vial and storage instructions to refrigerate at 2°C to 8°C, with warnings not to freeze or shake. Ingredients and preservative-free formulation details are also included.*

FDA Label Image

Figure 2 (Alymsys Bevacizumab Maly Injection 2)

A survival curve chart depicting the proportion of subjects surviving over 48 study months comparing two randomized treatments: chemotherapy alone (blue dashed line) and chemotherapy combined with Bevacizumab (red line). The y-axis shows survival proportion from 0 to 1.0, and the x-axis shows the study duration in months. A table below the graph lists the number of subjects at risk at various time points for each treatment group.*

FDA Label Image

Figure 3 (Alymsys Bevacizumab Maly Injection 3)

A Kaplan-Meier survival curve graph depicting the proportion surviving over a duration of up to 48 months. Two groups are compared: PC (blue line) and PC plus Bevacizumab (red line). The graph includes numbers of patients at risk for each group at various time points along the bottom.*

FDA Label Image

Figure 4 (Alymsys Bevacizumab Maly Injection 4)

A Kaplan-Meier survival curve chart showing progression-free survival over 24 months. It compares two groups: one treated with Bevacizumab plus IFN-alfa (blue line) and the other with Placebo plus IFN-alfa (red line). The vertical axis indicates the proportion progression-free, and the horizontal axis represents months. Patient numbers at risk for each group are shown below the chart over time.*

FDA Label Image

Figure 5 (Alymsys Bevacizumab Maly Injection 5)

A Kaplan-Meier survival curve chart showing the proportion of overall survival over time in months. It compares survival between two groups: chemotherapy alone (red line) and chemotherapy plus bevacizumab (blue line). The chart includes a legend identifying each group and a table of the number of patients at risk at various time points.*

FDA Label Image

Figure 6 (Alymsys Bevacizumab Maly Injection 6)

A Kaplan-Meier survival curve chart depicting progression-free survival over time in months. The y-axis shows the proportion progression-free, ranging from 0 to 1. Three curves represent different groups: CPF overall (blue dashed line), CPF less than 15 (red line), and CPF 15 or more (green line). A legend identifies the groups and sample sizes, and a table below shows the number of patients at risk at various time points.*

FDA Label Image

100 mg Label (Alymsys Bevacizumab Maly Injection 7)

ALYMSYS 100 mg/4 mL injection solution label for intravenous infusion by Amneal Pharmaceuticals LLC. The label includes storage instructions to refrigerate at 2°C to 8°C, caution against freezing or shaking, and notes no preservatives. It is a 4 mL single-dose vial with dosage information referencing prescribing details and dilution instructions using 0.9% Sodium Chloride Injection, USP.*

FDA Label Image

100mg Carton (Alymsys Bevacizumab Maly Injection 8)

ALYMSYS (bevacizumab-maly) Injection 100 mg/4 mL (25 mg/mL) preservative-free single-dose vial carton label. The product is for intravenous infusion after dilution, supplied in a 4 mL vial, and manufactured by Amneal Pharmaceuticals LLC in Bridgewater, NJ. The label includes storage instructions, contents, and usage precautions, with NDC 70121-1754-1, and indicates Rx only.*

FDA Label Image

400mg Label (Alymsys Bevacizumab Maly Injection 9)

ALYMSYS 400 mg/16 mL injection, solution for intravenous infusion, labeled as bevacizumab-maly. The label indicates a 16 mL single-dose vial containing 25 mg/mL concentration. It is manufactured by Amneal Pharmaceuticals LLC. Storage instructions recommend refrigeration at 2°C to 8°C, avoiding freezing or shaking, with a note that no preservatives are included. The label includes dilution instructions for intravenous use with 0.9% Sodium Chloride Injection.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.